ReviewFrontiers in neurology2019
Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research.
Review in Frontiers in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Long-Term Effects of Xenotransplantation of Human Enteric Glia in an Immunocompetent Rat Model of Acute Brain Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Brain repair mechanisms after cell therapy for stroke.Brain : a journal of neurology · 2024Review
- Stem Cell Therapy for Repair of the Injured Brain: Five Principles.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2024Article
- Biodegradable Microparticles for Regenerative Medicine: A State of the Art and Trends to Clinical Application.Polymers · 2022Review
- Neurofunctional and neuroimaging readouts for designing a preclinical stem-cell therapy trial in experimental stroke.Scientific reports · 2022Article
- Review
- Mesenchymal Stem Cells: Therapeutic Mechanisms for Stroke.International journal of molecular sciences · 2022Review
- Mesenchymal stem cells for regenerative medicine in central nervous system.Frontiers in neuroscience · 2022Review
- Human umbilical cord mesenchymal stem cells in type 2 diabetes mellitus: the emerging therapeutic approach.Cell and tissue research · 2021Review
- New Approaches in Nanomedicine for Ischemic Stroke.Pharmaceutics · 2021Review
- Recovery After Stroke: New Insight to Promote Brain Plasticity.Frontiers in neurology · 2021Article
- Mesenchymal Stem Cell-Based Therapy for Stroke: Current Understanding and Challenges.Frontiers in cellular neuroscience · 2021Review
- Translating intracarotid artery transplantation of bone marrow-derived NCS-01 cells for ischemic stroke: Behavioral and histological readouts and mechanistic insights into stem cell therapy.Stem cells translational medicine · 2020Article
- Article
- Application of Stem Cells in Stroke: A Multifactorial Approach.Frontiers in neuroscience · 2020Review
- Unveiling the Role of Inflammation and Oxidative Stress on Age-Related Cardiovascular Diseases.Oxidative medicine and cellular longevity · 2020Review
- Adult Stem Cells and Induced Pluripotent Stem Cells for Stroke Treatment.Frontiers in neurology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke is a major health problem worldwide. It has been estimated that 90% of the population attributable risk of stroke is due to risk factors such as aging, hypertension, hyperglycemia, diabetes mellitus and obesity, among others. However, most animal models of stroke use predominantly healthy and young animals. These models ignore the main comorbidities associated with cerebrovascular disease, which could be one explanation for the unsuccessful bench-to-bedside translation of protective and regenerative strategies by not taking the patient's situation into account. This lack of success makes it important to incorporate comorbidities into animal models of stroke in order to study the effects of the various therapeutic strategies tested. Regarding cell therapy, the administration of stem cells in the acute and chronic phases has been shown to be safe and effective in experimental animal models of stroke. This review aims to show the results of studies with promising new therapeutic strategies such as mesenchymal stem cells, which are being tested in preclinical models of stroke associated with comorbidities and in elderly animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.